Drug Trial Radar · NCT06963177
A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain
Last checked: Nov 20, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
May 26, 2025
Primary completion
May 15, 2028
Study completion Jan 6, 2030
Sponsor
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety and efficacy of GenSci048 for moderate to severe endometriosis-associated pain treatment.
Conditions
- Endometriosis-related Pain
Interventions
GenSci048Drug
Administered SC.
PlaceboDrug
Administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of dysmenorrhea (DYS) measured by Numeric Rating Scale (NRS)Time frame: baseline, week 24
- Change of non-menstrual pelvic pain (NMPP) measured by Numeric Rating Scale (NRS)Time frame: baseline, week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.